Department of Health and Human Services made the 63 SBIR and STTR awards below to small companies in the last two years, $72,472,750 obligated in all, through 2 offices. Every row links to the award's own federal record.
Award pages
| Starts | Company | Program | Amount |
|---|---|---|---|
| 2026-09-30 | Springwear, LLC | SBIR Phase II | $283,414 |
| 2026-09-30 | Advanced Life Technologies, LLC | SBIR Phase II | $143,736 |
| 2026-09-28 | Bhi Management Inc | SBIR | $2,295,326 |
| 2026-09-25 | Spike Neuro LLC | SBIR Phase II | $1,693,866 |
| 2026-09-22 | Research Triangle Institute | SBIR | $531,049 |
| 2026-09-18 | Biotherapeutics, Inc. | SBIR Phase I | $500,000 |
| 2026-09-18 | Mabswitch Inc | SBIR Phase II | $399,998 |
| 2026-09-18 | Cellfe, Inc | SBIR Phase II | $1,052,108 |
| 2026-09-15 | Vivacelle Bio Inc | SBIR Phase II | $690,878 |
| 2026-09-15 | Capienda Biotech, LLC | SBIR Phase I | $1,401,698 |
| 2026-09-09 | Neosplice Therapeutics, Inc. | SBIR Phase I | $406,500 |
| 2026-09-07 | Sollus Therapeutics, Inc. | STTR Phase I | $373,452 |
| 2026-09-07 | Keylicon Biosciences Inc | SBIR Phase II | $400,000 |
| 2026-09-07 | General Biophysics LLC | SBIR Phase I | $479,185 |
| 2026-09-05 | Amygo Solutions LLC | SBIR Phase I | $329,469 |
| 2026-09-01 | Cmtx Biotech Inc | STTR Phase I | $367,988 |
| 2026-09-01 | Rise Therapeutics LLC | SBIR Phase I | $1,042,478 |
| 2026-09-01 | Everest Biolabs, Inc. | SBIR Phase II | $1,153,043 |
| 2026-09-01 | Aventusoft L.l.c | SBIR Phase II | $500,000 |
| 2026-08-17 | Amissa Inc | SBIR Phase I | $504,222 |
| 2026-08-01 | Monod Bio, Inc. | SBIR Phase I | $377,260 |
| 2026-06-15 | Behavior Change Hub Limited Liability Company | STTR | $314,109 |
| 2025-09-25 | Syntr Health Technologies, Inc. | SBIR Phase I | $2,050,527 |
| 2025-09-24 | Mapp Biopharmaceutical, Inc. | SBIR Phase III | $1,986,788 |
| 2025-09-22 | Microbiotix, Inc. | STTR Phase I | $599,327 |
| 2025-09-22 | Natsar Pharmaceuticals, Inc. | SBIR Phase II | $2,250,000 |
| 2025-09-22 | Rendever, Inc. | STTR Phase I | $2,740,876 |
| 2025-09-16 | Exhalix, LLC | SBIR Phase II | $350,000 |
| 2025-09-16 | Mucommune LLC | SBIR | $2,292,701 |
| 2025-09-16 | Neurogt Inc | SBIR Phase II | $2,984,029 |
| 2025-09-15 | Biological Mimetics, Inc. | SBIR Phase II | $1,498,641 |
| 2025-09-15 | Chromologic LLC | SBIR Phase II | $1,499,763 |
| 2025-09-15 | L2 Diagnostics LLC | STTR Phase I | $599,954 |
| 2025-09-15 | Objective Biotechnology, Inc. | STTR Phase I | $803,099 |
| 2025-09-15 | Janusq LLC | SBIR | $698,011 |
| 2025-09-15 | Allander Biotechnologies, Inc. | SBIR Phase II | $2,300,000 |
| 2025-09-12 | Vivid Bioinnovations, Pbc | SBIR | $1,319,519 |
| 2025-09-09 | Fimbrion Therapeutics Inc | SBIR Phase II | $600,000 |
| 2025-09-05 | Cnd Life Sciences, Inc. | SBIR Phase II | $2,289,462 |
| 2025-09-01 | Objective Ed, Inc. | SBIR Phase I | $306,872 |
| 2025-09-01 | Good Nutrition Ideas LLC | SBIR Phase I | $385,000 |
| 2025-09-01 | Resuscitation Innovations LLC | SBIR Phase I | $498,453 |
| 2025-09-01 | Biosensics LLC | SBIR Phase II | $5,174,076 |
| 2025-08-25 | Immport Therapeutics Inc | SBIR Phase II | $592,254 |
| 2025-08-20 | Epoch Biotech, LLC | STTR Phase I | $498,709 |
| 2025-08-19 | Optimeos Life Sciences, Inc. | SBIR Phase I | $600,000 |
| 2025-07-24 | Pearl Diagnostics, Inc. | STTR Phase I | $1,976,387 |
| 2025-07-15 | Iotamotion, Inc. | STTR Phase I | $306,872 |
| 2025-07-01 | March Biosciences Inc | SBIR Phase II | $2,249,214 |
| 2025-06-12 | Astrocyte Pharmaceuticals Inc. | STTR Phase I | $2,999,688 |
| 2025-06-05 | Cisterna Biologics, Inc. | SBIR Phase I | $350,000 |
| 2025-05-16 | Taxis Pharmaceuticals Inc | SBIR Phase II | $2,000,000 |
| 2025-05-15 | Jillion Therapeutics Inc. | SBIR Phase I | $399,483 |
| 2025-05-15 | Stress Therapeutics, Inc. | SBIR Phase I | $1,994,840 |
| 2025-04-03 | Greenmark Biomedical Inc | SBIR Phase II | $294,632 |
| 2025-04-01 | Electronic Biosciences, Inc. | SBIR Phase I | $386,452 |
| 2025-04-01 | Myosin Therapeutics Inc | SBIR Phase II | $1,496,586 |
| 2025-03-01 | Corvion, Inc. | SBIR Phase II | $2,086,049 |
| 2025-02-01 | Mobile Health Interventions LLC | SBIR Phase II | $1,186,132 |
| 2024-12-20 | Vast Therapeutics, Inc. | SBIR Phase II | $1,988,594 |
| 2024-12-17 | Dare Bioscience, Inc. | SBIR Phase II | $2,000,000 |
More awards from Department of Health and Human Services
Cloverleaf Bio, Inc. (New Haven, CT)
SBIR award through National Institutes of Health: $300,000, starting 2025-09-15, ending 2027-09-14. FY25 concept award: Development of engineered trna therapeutics for clear cell renal cell carcinoma Industry 541715. Award 75N91025C00020.
Pathcision Medicine, Inc. (Watertown, MA)
SBIR award through National Institutes of Health: $299,981, starting 2025-08-11, ending 2027-02-10. Concept award for a novel delivery approach to transform metastatic pancreatic cancer treatment and prevention Industry 541714. Award 75N91025C00018.
Where this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.